Walmart eyes seniors in Medicare Advantage plans to fend off Amazon

With roughly a third of all Medicare beneficiaries, or 20 million people, enrolled in a Medicare Advantage (MA) plan, new entrants into the healthcare field are eyeing this hefty population. And retail giant Walmart is no exception, according to Forbes.

MA plans, which provide all Medicare benefits through contracts with private insurers, often offer more coordinated care at a lower overall cost. Walmart’s latest partnership with health insurer Anthem makes it clear the company intends to insert itself into the space.

The partnership will allow Anthem MA enrollees access to Walmart’s over-the-counter medications through allowances and could be just the first step in Walmart’s growing clout with insurers. Its move with Anthem is also another way the company is competing with Amazon, which has launched a number of its own healthcare initiatives, including an OTC business line, according to Forbes.

Walmart and Amazon are both looking to get a piece of the MA plan pie at a time when benefits are also expanding to include more non-medical services. Walmart has also been in recent talks to expand its partnership with Humana, one of the nation’s largest MA plans. Not to mention, Walmart has been rumored to potentially acquire Humana.

“As the likes of Amazon enter the prescription business, forging new upstream relationships in addition to its existing relationship with Humana for Part D will help solidify Walmart’s positioning as a major provider of healthcare services and health-related products for seniors,” Andrew Kadar, a managing director and partner in L.E.K. Consulting’s healthcare services practice, told Forbes.

Read the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.